SharpMed, LLC is pleased to announce its 6th issued United States patent. This 6th patent relates to our device called Turbo® O₂ – which was designed to reduce hypoxia with difficult intubations. In total, the company has applied for 22 critically important medical device patents with 16 pending at the United States Patent Office. “These 22 patents cover five of our flagship products in development – all of which will be clinically relevant to improve patient experience and outcomes” – Dr Chris Savino, MD, CEO.